|
ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics. Its clinical-stage testing products include ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase; ARQ 501, an intravenously administered novel activator of the cell's DNA damage response mechanism mediated by the E2F-1 transcription factor; and ARQ 171, an intravenously administered second generation activator of E2F-1. The company also provides ARQ 761, a second-generation E2F-1 compound to kill cancer cells while sparing normal cells through the direct activation of DNA damage response/checkpoint pathways; and has preclinical and research pipeline, which include Eg5 kinesin spindle protein and the B-RAF Kinase. It has an exclusive license agreement with Kyowa Hakko Kogyo co., Ltd. to develop and commercialize ARQ 197 in Japan and parts of Asia; and an alliance with Hoffmann-La Roche to discover and develop drug candidates targeting the E2F biological pathway. The company was founded in 1993 and is based in Woburn, Massachusetts.
|
